Stockscreener 앱 받기
11.00
0.82%
0.09
시장 영업 전:
11.05
0.05
+0.45%
전일 마감가:
$10.91
열려 있는:
$11.01
하루 거래량:
454.12K
Relative Volume:
0.66
시가총액:
$629.87M
수익:
-
순이익/손실:
$-59.85M
주가수익비율:
-12.42
EPS:
-0.8857
순현금흐름:
$-54.54M
1주 성능:
+1.85%
1개월 성능:
+18.28%
6개월 성능:
+547.06%
1년 성능:
+816.67%
1일 변동 폭
$10.64
$11.27
1주일 범위
$9.25
$11.27
52주 변동 폭
$1.16
$12.48
Climb Bio Inc Stock (CLYM) Company Profile
명칭
Climb Bio Inc
전화
1-866-857-2596
주소
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
11.00 | 624.71M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Mizuho | Outperform |
| 2026-03-24 | 개시 | B. Riley Securities | Buy |
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-11 | 개시 | Raymond James | Strong Buy |
| 2026-03-05 | 개시 | Wedbush | Outperform |
| 2026-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-10-16 | 개시 | William Blair | Outperform |
| 2025-10-13 | 개시 | H.C. Wainwright | Buy |
| 2025-08-15 | 개시 | Robert W. Baird | Outperform |
| 2025-06-06 | 개시 | Oppenheimer | Outperform |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
모두보기
Climb Bio Inc 주식(CLYM)의 최신 뉴스
Climb Bio to share antibody trial data at European renal congress - Stock Titan
Climb Bio Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentOpen Trading Community - Newser
Climb Bio teases key Budoprutug, CLYM116 readouts at BioConnect - MSN
Climb Bio Inc. (CLYM) Surges Over 3% – Approaching Key Resistance ZoneTrending Momentum Stocks - newser.com
Climb Bio, Inc. drives new focus on APRIL-targeted B cell therapies at Dallas workshop - Traders Union
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect - sharewise.com
Climb Bio, Inc.Common Stock (CLYM) Stock Price, News, Quote & History - FinancialContent
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Climb Bio (CLYM) and Boston Scientific (BSX) - The Globe and Mail
Climb Bio (CLYM) Stock Price, News & Analysis - MarketBeat
Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
Piper Sandler reiterates Climb Bio stock rating on IgAN opportunity By Investing.com - Investing.com Nigeria
Climb Bio, Inc. participates in HC Wainwright fireside chat to outline strategic direction - Traders Union
CLYM: Multiple clinical data readouts in 2024 will shape pivotal study plans and market positioning - TradingView
Piper Sandler reiterates Climb Bio stock rating on IgAN opportunity - Investing.com
Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Climb Bio (CLYM) price target increased by 18.34% to 19.62 - MSN
Climb Bio (CLYM) Q1 2026 Earnings: Why the Beat MattersFree Market Insights - Newser
Number of shareholders of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress - The Manila Times
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 ... - Caledonian Record
New immune thrombocytopenia antibody data headed to EHA 2026 - Stock Titan
H.C. Wainwright raises Climb Bio stock price target on trial progress - Investing.com Nigeria
Climb Bio to Present at Upcoming Investor Conferences - markets.businessinsider.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $20 - Moomoo
H.C. Wainwright raises Climb Bio stock price target on trial progress By Investing.com - Investing.com South Africa
Biotech Climb Bio plans May and June investor talks online - Stock Titan
TradingKey - TradingKey
Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN
Climb Bio (NASDAQ:CLYM) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Budo judo moves aplenty for Climb in autoimmune - BioWorld News
Baird Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $21 - Moomoo
Climb Bio, Inc. 1Q 2026: Net income $(13.7M), EPS $(0.20) — 10-Q Summary - TradingView
Climb Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Climb Bio (NASDAQ: CLYM) trims Q1 2026 loss and raises $110M to fund pipeline - Stock Titan
[8-K] Climb Bio, Inc. Reports Material Event - Stock Titan
$110M financing gives Climb Bio room for multiple 2026 drug data readouts - Stock Titan
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $19 to $22 - Moomoo
Wedbush Adjusts Price Target on Climb Bio to $15 From $14, Maintains Outperform Rating - Moomoo
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - Yahoo Finance
Climb Bio Secures 110 Million Dollars Through Private Stock Placement - HarianBasis.co
Climb Bio reports B-cell depletion data for budoprutug trial By Investing.com - Investing.com South Africa
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - Insider Monkey
Climb Bio Inc (CLYM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Climb Bio Inc 주식 (CLYM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thomas Stephen Basil | Director |
Feb 26 '26 |
Sale |
7.01 |
16,313 |
114,289 |
154,657 |
2.98%
1.33%
자본화:
|
볼륨(24시간):